Propofol sedation for longitudinal pediatric neuroimaging research.

Journal Article (Clinical Trial;Journal Article)

There is disagreement about allowing propofol sedation for research magnetic resonance imaging/spectroscopy (MRI/MRS) in children. Our study is the first to provide relevant safety and efficacy data. With institutional approval, 108 research MRI/MRS procedures under propofol sedation were performed longitudinally on children at ages 3-4 years (N=59) and 6-7 years (N=49). Sedation parameters, physiological values, and outcome data were collected. Success rate for acquisition of satisfactory quality MRI/MRS during propofol sedation was compared with that in typically developing, age-matched sleeping children. Only 5 minor events (2 with need to insert an oral airway, 2 with premature termination of study, 1 with bradycardia not requiring treatment) and no major events occurred. These safety/efficacy data are equal to or better than previously reported with propofol for clinically indicated procedures. A high percentage of parents of children participating in MRI/MRS studies at 3-4 years of age returned with their child at 6-7 years of age, and longitudinal follow-up was not adversely impacted by their child's experience with sedation. The success rate of data acquisition was significantly higher during propofol sedation (98%) than during late-night sleep studies in typically developing children (30%-50%). We conclude that propofol sedation for research MRI/MRS is safe and effective when children of appropriate ASA class are selected, supplemental oxygen is delivered, and sedation and monitoring are done by an experienced anesthesiologist.

Full Text

Duke Authors

Cited Authors

  • Amundsen, LB; Artru, AA; Dager, SR; Shaw, DWW; Friedman, S; Sparks, B; Dawson, G

Published Date

  • October 2005

Published In

Volume / Issue

  • 17 / 4

Start / End Page

  • 180 - 192

PubMed ID

  • 16184061

International Standard Serial Number (ISSN)

  • 0898-4921

Digital Object Identifier (DOI)

  • 10.1097/01.ana.0000171734.63879.fd


  • eng

Conference Location

  • United States